According to a study, immunotherapy drugs are well tolerated by patients with lung cancer who have limited physical function.

Published Date: 22 Nov 2023

Durvalumab, an immune checkpoint inhibitor medication, is safe and may improve overall survival for patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, per a new study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

2.

Do Anatomy Atlases Reflect Social Inequalities?

3.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

4.

Some triple negative breast cancers might be avoided by longer breastfeeding

5.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot